Editorially independent · We do not sell peptides
An independent project from Amsterdam, covering all 27 EU member states

An independent
record of every
peptide circulating
in Europe.

Peptidepedia catalogues 1,200+ compounds across cosmetic, recovery, longevity, metabolic, cognitive and hormonal classes — grades the evidence behind every claim, tracks regulatory status across 27 jurisdictions in real time, and publishes critical reporting on the brands selling them.

Compounds tracked
59 · 0 this week
Jurisdictions
27 · EU + UK + CH
Status changes / 2026
0 · logged
REG · RECOVERY
▲ LIVE
SEQ · 15 AA
REF · 2026-MAY
G P L V A R Y D K SEQ · GLY-GLU-PRO-PRO-PRO-GLY-LYS-PRO-ALA-ASP-ASP-ALA-GLY-LEU-VAL · MW 1419.5
BPC-157
EVIDENCE · C
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
EU AUTHORISED No — research use only
MARKETED IN NL Grey market, unlicensed
LAST UPDATE 18 MAY 2026
EU Regulatory Wire
18:42 NL CBG/MEB issues advisory on compounded GLP-1 analogues — pharmacies cited 17:30 DE BfArM tightens import controls on research peptides from third countries 15:11 FR ANSM opens consultation on Melanotan II cosmetic claims 13:58 IT AIFA confirms Semaglutide shortage extended through Q3 11:04 EU EMA publishes Annex IV update — Tirzepatide off-label monitoring 09:22 UK MHRA seizes shipments labelled BPC-157 at Heathrow 08:15 CH Swissmedic warns against online sale of CJC-1295 18:42 NL CBG/MEB issues advisory on compounded GLP-1 analogues — pharmacies cited 17:30 DE BfArM tightens import controls on research peptides from third countries 15:11 FR ANSM opens consultation on Melanotan II cosmetic claims 13:58 IT AIFA confirms Semaglutide shortage extended through Q3 11:04 EU EMA publishes Annex IV update — Tirzepatide off-label monitoring 09:22 UK MHRA seizes shipments labelled BPC-157 at Heathrow 08:15 CH Swissmedic warns against online sale of CJC-1295
§ 01 — THE ENCYCLOPEDIA

Every compound, graded — not sold.

A reference catalogue. Each entry contains structural data, mechanism, primary literature, regulatory cross-reference, and our independent evidence grade. We never accept payment from manufacturers or sellers.
Search 59 compounds, INN names, brand names…
SHOWING 8 / 59
# Compound Category Evidence EU Status Last reviewed
001. Oxytocin
INN · oxytocinum · C₄₃H₆₆N₁₂O₁₂S₂ · MW 1007.2
 Hormonal
Endogenous nonapeptide hormone · uterine smooth-muscle contraction, milk let-down
S
 AUTHORISED 18 MAY 2026
002. Semaglutide
INN · semaglutidum · C₁₈₇H₂₉₁N₄₅O₅₉ · MW 4113.6
 Metabolic
GLP-1 receptor agonist · once-weekly subcutaneous
S
 AUTHORISED 18 MAY 2026
003. Tirzepatide
INN · tirzepatidum · C₂₂₅H₃₄₈N₄₈O₆₈ · MW 4813.5
 Metabolic
Dual GIP / GLP-1 receptor agonist · once-weekly subcutaneous
S
 AUTHORISED 18 MAY 2026
004. Bremelanotide
INN · bremelanotidum
 Hormonal
Melanocortin (MC1R/MC3R/MC4R) receptor agonist · on-demand subcutaneous
A
 NOT AUTHORISED 18 MAY 2026
005. Setmelanotide
INN · setmelanotidum
 Hormonal
MC4R-selective melanocortin receptor agonist · daily subcutaneous
A
 AUTHORISED 18 MAY 2026
006. Tesamorelin
INN · tesamorelinum
 Metabolic
Synthetic GHRH analogue · stimulates pituitary GH release · daily subcutaneous
A
 AUTHORISED 18 MAY 2026
007. Cagrilintide
INN · cagrilintidum
 Metabolic
Long-acting amylin receptor agonist · weekly subcutaneous · investigational
B
 NOT AUTHORISED 18 MAY 2026
008. GHK-Cu
C₁₄H₂₃CuN₆O₄ · MW 405
 Cosmetic
Copper-bound tripeptide · skin-barrier modulator, wound-healing adjunct
B
 AUTHORISED 18 MAY 2026
Page 1 / 8 — 59 entries indexed
Open the full Encyclopedia →
§ 02 — REGULATORY

State of the Compound — 27 jurisdictions, one source of truth.

A live record of how each member state classifies, restricts, authorises or prohibits every compound in the registry. Updated within 24 hours of any official notice.
Semaglutide
GLP-1 R-Agonist · Metabolic
NL
Nederland
BE
België
DE
Deutschland
FR
France
IT
Italia
ES
España
AT
Österreich
PT
Portugal
IE
Éire
DK
Danmark
SE
Sverige
FI
Suomi
PL
Polska
CZ
Česko
SK
Slovensko
HU
Magyar.
RO
România
BG
България
EL
Ελλάδα
HR
Hrvatska
SI
Slovenija
EE
Eesti
LV
Latvija
LT
Lietuva
LU
Lux.
MT
Malta
CY
Κύπρος
CH
Schweiz +
UK
United K. +
NO
Norge +
Authorised — prescription
Restricted / supply controls
Prohibited / not authorised
Unclassified
Status changelog
Updating
14 MAY · 09:22
NL
BPC-157 — promotional claimsCBG/MEB orders three webshops to halt “tendon recovery” marketing pending Article 86 review.
DOWNGRADE
12 MAY · 16:08
DE
Tirzepatide — supply restoredBfArM lifts dispensing restriction following resolution of Eli Lilly supply notice 04/26.
UPGRADE
09 MAY · 11:44
FR
Melanotan II — cosmetic banANSM publishes Décret 2026-318 prohibiting Melanotan II in leave-on cosmetic products. In force 01.07.2026.
PROHIBIT
07 MAY · 14:30
EU
Annex IV — GLP-1 monitoringEMA expands post-authorisation monitoring to compounded analogues. National authorities notified.
REVISION
03 MAY · 08:50
UK
BPC-157 — border seizureMHRA reports seven shipments seized at Heathrow LHR-7. Mislabelled as “cosmetic raw materials”.
ENFORCEMENT
28 APR · 19:12
CH
CJC-1295 — public warningSwissmedic issues consumer warning following adverse event cluster, four hospitalisations.
WARNING
22 APR · 10:05
ES
GHK-Cu — cosmetic clarificationAEMPS confirms inclusion as cosmetic ingredient at concentrations ≤ 0.05% — no marketing-authorisation required.
CLARIFY
18 APR · 14:48
BE
Selank — schedule review openedFAGG/AFMPS opens public consultation on scheduling of synthetic tuftsin analogues. Closes 30 June 2026.
CONSULT
§ 03 — METHOD

An evidence grade for every claim.

We grade compounds on the strength, independence and replication of evidence supporting their marketed use — not on whether they "work" in principle.
3 compounds
S
Standard of care
Multiple high-quality, independent RCTs. Authorised by EMA or national agency. Established mechanism.
3 compounds
A
Strong
≥2 well-powered RCTs in humans with consistent effect size. Plausible mechanism. No major contradictory data.
9 compounds
B
Moderate
One adequately-powered human trial, plus supportive in-vitro / animal data. Effect plausible, not yet replicated.
13 compounds
C
Limited
Pilot or open-label human data only. Or strong preclinical evidence without translation. Caution warranted.
30 compounds
D
Anecdotal
No clinical evidence. User reports, forum data, vendor claims. Mechanism may be speculative or extrapolated.
1 compound
F
Refuted
High-quality trial(s) have failed to demonstrate the claimed effect, or known harms outweigh the marketed benefit.
Editor's note — funding & methodology

The methodology is publicly documented so readers can audit every grade against its source papers. We accept no money from manufacturers, importers, compounding pharmacies, telehealth clinics, or peptide resellers; we do not run affiliate links, sponsored content, or paid placements.

§ 04 — BRAND DOCKET

Critical, scored reviews — without affiliate links.

We assess every brand selling into the European market on quality of evidence, claims discipline, supply-chain transparency, regulatory compliance, and customer recourse.
Issue 042 · LEAD REVIEW AVOID
Helios Bioactives — Rotterdam
2.1/ 10
Editor
M. van Doorn
“Three of the seven products we tested contained less than 60% of the labelled peptide content. Two contained a different compound altogether. The company refused our request for a Certificate of Analysis.”
Evidence claims
D · overreach
Lab purity
38–94%
Reg. compliance
3 / 12
Ships to
EU + UK + CH
Tested
7 products
Read
Full dossier →
Cosmetic peptides CLEARED
Nordlys Skin Lab
7.8/ 10
“Disciplined claims, third-party COAs published, no off-label suggestion.”
Evidence
B · honest
Compliance
11 / 12
Read
Review →
Metabolic compounding WATCH
Stadtklinik Apotheke
5.2/ 10
“Operates within compounding exemption, but volume and marketing reach raise questions about Article 5(1) reliance.”
Compounding
Active
Compliance
7 / 12
Read
Review →
Online retail AVOID
PeptideLab.eu
1.4/ 10
“Sells unapproved compounds with explicit therapeutic claims. Refused all correspondence over six months.”
Reg. flags
11 active
Compliance
0 / 12
Read
Dossier →
Recovery clinic WATCH
Atlas Performance
4.6/ 10
“Clinically supervised but routinely prescribes Grade-C compounds with overstated mechanism claims.”
Supervision
MD + RN
Claims
Overstated
Read
Review →
§ 05 — INVESTIGATIONS

The reporting nobody selling these has incentive to fund.

Long-form investigative pieces — six to twelve weeks of work each — drawing on freedom-of-information requests, lab testing, and direct interviews.
[ EDITORIAL PHOTO · Rotterdam port, container inspection ] Cover · 6 weeks reporting
Investigation · 4-part series

How “research-only” peptides reach 40,000 European customers a month — and the Rotterdam pharmacy that supplies most of them.

Six weeks of port records, supplier interviews and independent assay testing reveal a supply chain hiding in plain sight inside the EU's compounding exemption. We name the importers, the broker, and the compounding pharmacy at the centre.

By M. van Doorn, S. Klein · 4,800 words Read part one →
[ DOCUMENT IMAGE · annotated COA ] Lab assays
Field test

We tested every “BPC-157” sold to Dutch consumers. Half were something else.

Independent HPLC-MS testing of 22 products purchased anonymously. Four contained no peptide at all.

L. Aydın · 2,100 words →
[ DIAGRAM · GLP-1 supply network ] Data piece
Data investigation

The German compounding loophole keeping cheap GLP-1 alive — for now.

How §13 AMG creates a legal shelter that the EMA is no longer willing to defend in court.

P. Reuter · 3,400 words →
★ THE COMPOUND — Weekly briefing

The week's regulatory changes,
graded studies, and brands
worth your attention — in one email.

Friday mornings. Six minutes to read. Every status change in the EU + UK + CH, two new compound entries, the studies our editors thought mattered, and one investigation update. Free to read.

Subscribers
42,308 EU + UK
Open rate
68% 52-wk avg.
Editions sent
112 since Mar 2024
NO ADS · NO TRACKING · NO AFFILIATE LINKS · UNSUBSCRIBE IN ONE CLICK